2012年1月
Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma
JAPANESE JOURNAL OF RADIOLOGY
- 巻
- 30
- 号
- 1
- 開始ページ
- 62
- 終了ページ
- 68
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s11604-011-0010-2
- 出版者・発行元
- SPRINGER
We report our initial experience with the transarterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC) using cisplatin-conjugated gelatin microspheres (Cis-GMS).
Nineteen patients with 25 HCC nodules (mean diameter 23.0 mm) were treated by selective TACE using 50- to 100-mu m Cis-GMS. Tumor necrosis and postembolization syndrome were assessed during the follow-up. The tumor response was evaluated on contrast-enhanced computed tomography images at 1 and 3 months after TACE using Cis-GMS.
All procedures were technically successful in all patients; following the TACE using Cis-GMS, there were no major complications, and postembolization syndrome was minimal. At the 1-month follow-up, the response rate was 12 of the 25 (48%) and 21 of the 25 (84%) HCC nodules based on RECIST 1.1 and EASL criteria, respectively; at the 3-month follow-up, it was 10 of the 25 (40%) and 14 of the 25 (56%) HCC nodules, respectively.
Our initial experience with using Cis-GMS for TACE suggests that these drugs may represent an optimal treatment option for the treatment of advanced HCC and that the use of gelatin microspheres loaded with chemotherapeutic agents warrants further study.
Nineteen patients with 25 HCC nodules (mean diameter 23.0 mm) were treated by selective TACE using 50- to 100-mu m Cis-GMS. Tumor necrosis and postembolization syndrome were assessed during the follow-up. The tumor response was evaluated on contrast-enhanced computed tomography images at 1 and 3 months after TACE using Cis-GMS.
All procedures were technically successful in all patients; following the TACE using Cis-GMS, there were no major complications, and postembolization syndrome was minimal. At the 1-month follow-up, the response rate was 12 of the 25 (48%) and 21 of the 25 (84%) HCC nodules based on RECIST 1.1 and EASL criteria, respectively; at the 3-month follow-up, it was 10 of the 25 (40%) and 14 of the 25 (56%) HCC nodules, respectively.
Our initial experience with using Cis-GMS for TACE suggests that these drugs may represent an optimal treatment option for the treatment of advanced HCC and that the use of gelatin microspheres loaded with chemotherapeutic agents warrants further study.
- リンク情報
- ID情報
-
- DOI : 10.1007/s11604-011-0010-2
- ISSN : 1867-1071
- Web of Science ID : WOS:000300289500009